<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00182000</url>
  </required_header>
  <id_info>
    <org_study_id>2003-P-001325</org_study_id>
    <nct_id>NCT00182000</nct_id>
  </id_info>
  <brief_title>Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Medication Trial With D-Cycloserine for Individuals With OCD Currently Receiving Behavior Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      This study will assess the effectiveness of Seromycin (D-cycloserine) in enhancing the
      positive effects of behavior therapy for people with Obsessive-Compulsive Disorder (OCD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hope to enroll 50 subjects in a double-blind, placebo-controlled study of D-cycloserine
      augmentation of behavior therapy for Obsessive-Compulsive Disorder. All subjects will undergo
      a pre-treatment assessment, and then be randomly assigned to receive Seromycin (100 mg) or
      placebo one-hour before each of 10 therapy sessions. Subjects will then come in for a
      treatment planning session and the behavior therapy sessions delivered twice weekly for 5
      weeks. Comprehensive assessments of obsessive-compulsive symptoms, mood state, and cognitions
      will be given at baseline, after 5 treatment sessions, after 10 sessions and 1 month and 6
      months post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale-Brown Obsessive Compulsive Scale (YBOCS)</measure>
    <time_frame>Post-treatment (week 5)</time_frame>
    <description>A clinician-rated measure of obsessive-compulsive disorder severity. Each item is scored on a 0 to 4 range. Total scores are obtained by summing items 1-10 and thus range from 0 to 40 with higher scores indicating greater symptom severity. Results posted below are from the post-treatment evaluation (after 10 treatment sessions).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions Scale (CGI)</measure>
    <time_frame>Post-treatment (week 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>Post-treatment (week 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Inventory (BAI)</measure>
    <time_frame>Post-treatment (week 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obsessional Beliefs Questionnaire (OBQ)</measure>
    <time_frame>Post-treatment (week 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form Health Survey (SF-36)</measure>
    <time_frame>Post-treatment (week 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability Inventory</measure>
    <time_frame>Post-treatment (week 5)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Seromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>seromycin</intervention_name>
    <description>100mg tablet administered 1 hour prior to each therapy session</description>
    <arm_group_label>Seromycin</arm_group_label>
    <other_name>D-Cycloserine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavior Therapy</intervention_name>
    <description>10 weekly hour-long behavior therapy sessions</description>
    <arm_group_label>Seromycin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Structured Clinical Interview for DSM-IV (SCID) diagnosis of Obsessive Compulsive
             Disorder

          -  Score of greater than 16 on the Yale-Brown Obsessive Compulsive Scale

          -  Negative urinary beta-Human Chorionic Gonadotropin (hCG) test

        Exclusion Criteria:

          -  Currently taking or have taken an unstable dose of psychotropic medications within 2
             months prior to enrollment

          -  Currently taking medications that may interfere with the study medication

          -  History of seizure disorder or other serious medical illnesses (e.g., cardiovascular,
             liver, kidney, respiratory, endocrine, neurologic, or blood-related disease)

          -  Current diagnosis of tuberculosis

          -  Other psychiatric diagnoses (e.g., alcohol dependence, bipolar disorder, psychosis,
             organic mental disorder, or development disorder) that are of greater concern than the
             obsessive-compulsive disorder diagnosis

          -  Currently taking medications that may lower seizure threshold (e.g., including
             clozapine, pethidine, and the following antibiotics in high dosage: penicillins,
             cephalosporins, amphotericin, and imipenem)

          -  Poses a serious suicidal or homicidal threat

          -  Currently undergoing psychotherapy

          -  Failure to benefit from ten or more sessions of previous Exposure and Response
             Prevention (ERP) treatment

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Wilhelm, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>May 1, 2012</results_first_submitted>
  <results_first_submitted_qc>June 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 6, 2012</results_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Sabine Wilhelm</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>OCD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>33 participants enrolled in the study. However, 4 participants decided not to participate in between consenting and starting treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Seromycin</title>
          <description>10 twice-weekly sessions of behavior therapy plus 100mg tablet of seromycin</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>10 twice-weekly sessions of behavior therapy plus 100mg tablet of placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Seromycin</title>
          <description>10 twice-weekly sessions of behavior therapy plus 100mg tablet of seromycin</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>10 twice-weekly sessions of behavior therapy plus 100mg tablet of placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.29" spread="13.01"/>
                    <measurement group_id="B2" value="38.07" spread="12.28"/>
                    <measurement group_id="B3" value="38.18" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Yale-Brown Obsessive Compulsive Scale (YBOCS)</title>
        <description>A clinician-rated measure of obsessive-compulsive disorder severity. Each item is scored on a 0 to 4 range. Total scores are obtained by summing items 1-10 and thus range from 0 to 40 with higher scores indicating greater symptom severity. Results posted below are from the post-treatment evaluation (after 10 treatment sessions).</description>
        <time_frame>Post-treatment (week 5)</time_frame>
        <population>Thirty-three participants were enrolled. Four participants decided not to participate in between enrolling and beginning treatment. Six participants withdrew from the study before the mid-treatment evaluation; 1 participant withdrew from the study after the mid-treatment evaluation, and this participant's data was carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Seromycin</title>
            <description>10 twice-weekly sessions of behavior therapy plus 100mg tablet of seromycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10 twice-weekly sessions of behavior therapy plus 100mg tablet of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Yale-Brown Obsessive Compulsive Scale (YBOCS)</title>
          <description>A clinician-rated measure of obsessive-compulsive disorder severity. Each item is scored on a 0 to 4 range. Total scores are obtained by summing items 1-10 and thus range from 0 to 40 with higher scores indicating greater symptom severity. Results posted below are from the post-treatment evaluation (after 10 treatment sessions).</description>
          <population>Thirty-three participants were enrolled. Four participants decided not to participate in between enrolling and beginning treatment. Six participants withdrew from the study before the mid-treatment evaluation; 1 participant withdrew from the study after the mid-treatment evaluation, and this participant's data was carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="7.2"/>
                    <measurement group_id="O2" value="14.5" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions Scale (CGI)</title>
        <time_frame>Post-treatment (week 5)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory (BDI)</title>
        <time_frame>Post-treatment (week 5)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Anxiety Inventory (BAI)</title>
        <time_frame>Post-treatment (week 5)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Obsessional Beliefs Questionnaire (OBQ)</title>
        <time_frame>Post-treatment (week 5)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-Form Health Survey (SF-36)</title>
        <time_frame>Post-treatment (week 5)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disability Inventory</title>
        <time_frame>Post-treatment (week 5)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Seromycin</title>
          <description>10 twice-weekly sessions of behavior therapy plus 100mg tablet of seromycin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>10 twice-weekly sessions of behavior therapy plus 100mg tablet of placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sabine Wilhelm, PhD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6177246146</phone>
      <email>swilhelm@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

